Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P51 vs Keytruda plus platinum-pemetrexed in first-line metastatic non-squamous NSCLC
2024-514048-98-00Phase 3Completed
- Sponsor
- Celltrion
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in non-squamous non-small cell lung cancer (2 arms), sponsored by Celltrion. Primary endpoint: Objective response rate (ORR) by RECIST 1.1. Started Dec 2024; status: completed.
02
Drugs
03
Conditions
non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on 2024-514048-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514048-98-00.